-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PLtvv3Q6hbEe6kRTHo/vALZoMw4RJytGfTAnAX+2Ua3Cf35rjoS/qKAtYyu7Wxdh
 aZmTYuz1y9ep1T7DT8MwIw==

<SEC-DOCUMENT>0001193125-10-225539.txt : 20101007
<SEC-HEADER>0001193125-10-225539.hdr.sgml : 20101007
<ACCEPTANCE-DATETIME>20101007103455
ACCESSION NUMBER:		0001193125-10-225539
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101007
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101007
DATE AS OF CHANGE:		20101007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		101113090

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): October&nbsp;7, 2010 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01 Other Events </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;7, 2010, ARCA biopharma, Inc., or ARCA, issued a press release announcing that the European Patent Office has issued a
patent on methods of treating heart failure patients with bucindolol based on genetic targeting. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma announces European patent issued for treating heart failure patients with bucindolol based on genetic targeting&#148;, dated October 7,
2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: October&nbsp;7, 2010 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael R. Bristow</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Michael R. Bristow</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: &nbsp;&nbsp;President and Chief Executive Officer</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma announces European patent issued for treating heart failure patients with bucindolol based on genetic targeting&#148;, dated October 7,
2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g106006g95a16.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES EUROPEAN PATENT ISSUED FOR TREATING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HEART FAILURE PATIENTS WITH BUCINDOLOL BASED ON GENETIC </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TARGETING </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bucindolol
Patents Issued in United States, Europe and Russia </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, October&nbsp;7, 2010</I> &#150; ARCA biopharma, Inc. (Nasdaq:
ABIO), a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that the European Patent Office has issued a patent on methods of treating heart failure patients with
bucindolol based on genetic targeting. The patent (European Patent Number 1802775) entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting,&#148; provides protection for this novel approach to treating patients with heart
failure in France, Germany, Netherlands, Switzerland/Liechtenstein, Great Britain, Ireland, Luxembourg, Monaco, Spain, Italy and Sweden. ARCA had previously announced receipt of the European Patent Office Communication under Rule 71(3) EPC notice of
intent to grant a European patent for this patent application. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heart failure is one of the largest health care problems
in the world. Industry sources estimate that approximately 14&nbsp;million people in Europe currently suffer from heart failure and this number is forecast to increase to 30&nbsp;million by the year
2020.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Over 3.6&nbsp;million new cases of heart failure
are reported each year in Europe.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are obviously pleased with the European Patent Office&#146;s issuance of this patent, which we believe will extend our pharmacogenetic
intellectual property protection around bucindolol and, if approved for marketing, provide Gencaro market exclusivity in the designated countries into 2025,&#148; said Michael R. Bristow, President and Chief Executive Officer of ARCA. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About
Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM
</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is an oral tablet
formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would
otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro is well-tolerated in patients with advanced HF. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;17, 2010, ARCA announced that it reached agreement with the U.S. Food and Drug Administration
(FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most
favorably to bucindolol. An SPA is an agreement with the FDA that the proposed trial protocol design, clinical endpoints and statistical analyses are acceptable to support regulatory approval. The FDA has previously designated as a Fast Track
development program the investigation of Gencaro for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. In March 2010, ARCA was awarded a patent from the U.S. Patent and
Trademark Office on methods of treating heart failure patients with bucindolol based on genetic testing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Heart Failure
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heart failure, or HF, is a chronic, progressive condition in which a problem with the structure or function of the heart impairs its
ability to supply sufficient blood flow to meet the body&#146;s needs for blood and oxygen. Common causes of heart failure include myocardial infarction and other forms of ischemic heart disease, hypertension, valvular heart disease and
cardiomyopathy. Heart failure is one of the largest health care problems in the United States and the rest of the world. Industry sources estimate that about 5.7&nbsp;million Americans have HF and nearly 670,000 new patients are diagnosed annually.
In addition, HF is the underlying reason for approximately 12 to 15&nbsp;million annual visits to physicians, 6.5&nbsp;million annual hospital days and over $37 billion in direct and indirect annual healthcare costs in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beta-blockers are part of the current standard of care for HF, and are considered to be among the most effective drug classes for the disease. However, a
significant percentage of eligible patients in the United States is not being treated with, or does not tolerate or respond well to, the beta-blockers currently approved for the treatment of HF. ARCA believes that new therapies for which patient
response can be predicted before a drug is prescribed can help improve the current standard of practice in the treatment of HF. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA
biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for heart failure and other
cardiovascular diseases. The Company&#146;s lead product candidate,
Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to
be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reference: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 &#150; SHAPE (Study group on
Heart failure Awareness and Perception in Europe) Survey Results to the General Public, Annual Congress of the European&nbsp;Society of Cardiology in Vienna, September 2003. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform
Act of 1995. These statements include, but are not limited to, statements regarding the issuance of, and protection provided by, European Patent 1802775 entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting&#148; and
statements regarding regulatory review and potential approval of the Company&#146;s New Drug Application for Gencaro; and the Company&#146;s ability to fund future operations. Such statements are based on management&#146;s current expectations and
involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with:
the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including
without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2009 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g106006g95a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g106006g95a16.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4@#?`P$1``(1`0,1`?_$`,@```(!!`,!````````
M```````("0$&!PH"`P0%`0$``00#`0``````````````!P$"`P@%!@D$$``!
M!`$#`P$%!`4*`P4)```!`@,$!08`$0<A$@@3,4$B%`E183(5<9%B(PJ!X4)2
M<J+",Q87H<$DL9+25!C10Y,E-2:V9RD1``(!`P$%!`8&!`@/```````!`A$#
M!`4A,1(&!T%1(A-A<8$R%`GPD:$C%0BQ8M)3P4)CLS14E"71X5*BLG.#DR2D
M174F-CC_V@`,`P$``A$#$0`_`-^FQLHE5$?GSWV(D**RY(E2Y3[<>-&8:'<Z
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M/]7PRI19#?<`/R#V[N?R;:S1^9%CRQXY+Y)S5:DI?]1M['&FS^B>DS1Z,R>3
M\,]3MIJ-:^3+]'F'S7?J*PV4@N\.VZ-UE!2K,(05\.Q64C\@^+L!!U\UGYEN
M!=BG+DO,BY04E_>-KMK5?T3LI]IDM]%+MV*E#4[;;;5/)EV4_E/29HXL\T^+
M.2;&+12VK#"[V<M+4&-?+956SGE*2CT(MPP`P)!4H!*'T,*4?9J>.D_YW>DW
M4O*CI6=/\(UV<XPC9NW8W:RDZ)<:C;[=GNG4>8^F>OZ!6Y!?$8T4VY1BXM);
MWP[=WK&W1*"QOV$;?:KW[[';<`D#[?U:W)4TWQ1H['`I*2VJ5>[V4>_M(Y=5
M-P2JUO\`0=GKC^J?UC54TU5;45V=FU!ZX_JG]8U4'2_.:BM/2)*FH\:.RY(?
MDOOM,LLL--EQUUY;A2EEMI"2I2E$)2D$D@:`ZXEG&G,,RHCC4J))9;D1I<5]
MJ3%DQWD][+S$ADK9>:>;(6A25*2I!!WZZ`]7KC^J?UC0!ZX)2D).ZCL.BB!T
MWZE*5=HZ>T[#0%4NJ4-PTX.FX[AVG^4'J#]V@*!Y1_\`<N;^\;;=/N*M@=`5
M]4@'=IP'KL!VDG;^78=/MT!3UQ_5/ZQH`]<?U3^L:`"^D=2D]/O'_/;WZ`^5
M;Y)18\RF3?W%31QE[=DBXM(%8RLGW)<G2(Z"1]F^@/B5_).`6Z@W4YQA=J[O
MMZ=;E='-5O\`U0(\Q:R?Y!H"[/F3LDAE92LI"5@A2%=Y`20I'<GM/<-C[]^F
M@.P/CWI(/O&^^Q]X]V@#UQ_5/ZQH#QS+>!7,MR)\J+`CNR(\1M^=*C0FERI;
MB&8D=#DEUI*WI;[@0T@$K6L[`$Z`]8D`[[H4-CL=_82`-]C[P"=`5]<?U3^L
M:`[`O='?MTV)V_1O_P"S0$='U!\\MJG'\-P&M=<8AY6Y:6E[Z:RW\Y`HU0A%
MKU'^FT_-E!2D>Q00-^G37FS\Q#J7K'+G+NE\@:3X'K-N_<G<4J34+$K<7%+M
MKYM?82]TJT6WF9%_59->9C2@HI_K*3;^PCBPS"';^8TTTV@2UG_HVGO32I_O
M/<IAIYL%*7R>B4JV/NVUY5\G\AW^9M0_"[$)6<3A\-8OCO3[DWM;>U[$3SJ.
MLW]-MN5WAE:E&C:W07?)K=[1I<*XE3:P;6O,-S\UK67+1B&H=KZDQ7$MVU=L
M=E)DH:<#R01O^[(]^MQ>G?0O%U+3;V/>@WJ6/#B\MK[RB_C</O4]-"-<_FV=
MJ:R+>W';IQ+<WZ]Q>LSB(KQC%'8D)3S]A97L9I`0.]QWUZ]$9/X>X%P%0'V#
M?[-2%+HCIU[D32K^/;4\G/U*[&B57PORZ;%V;3BX<W.6IN<[B7@VU=/9ZUVF
M,<WXD*+55%51ER'J]/R;OII"_F)C*"Y9O^H?W;,5I\+2'5*`2V@>_4,=0>BL
M<+5GIVET7PEI*4E[L9;:QD]R:IN9V#2.8[ZM1N.M')M/UT%4R;'%5,QT-.)>
M])92IQK=M"EH((]!X@*Z'\*M_:-Q[M:A\P:'?Y=U>;T^EG58.L;M>&LUNX=J
MJZ]Q)^%E7=7L\&3*"L-4E6FY[]Y-=XF9U8\@<)8U9W#SLJUJ'YV,S)KJU.O3
M13/^G$DON+W4MU<%UKO43U4#KWX_*#U'U#J-T,T_6-5XKF=CW)8TWM;<K:CO
M]-)*J[FC4KG[3;.@\Q7\>PDXW/%%+N=5L&8'0`:V=3BU6'NG2+4'"VHRWH-5
M,A"U]<SRBD\$>'UIQIBLIU/(WD6_.P*N:B)<785O'L"&+3DW(0F+W/HA,T24
M05.J`0@3B3^'0'1]!_R5'./A14\<W$XRLT\<+;_;2>A]WU)CF&/M*M./YKBE
M+4X\VFI6Y!"R!N8.WMT!-9H"R>1N/L6Y6P?)>.<WAR[#$<OK'JG((4"WN*";
M(@.%#BD1+K'IM;=UD@.-I*78S[;@VV!VWT!J8_65\4T^"E'Q'R5XU<V>16&T
M7(F4Y!A][@LWG7D>\JZV5!I?SN#;X]/L;]=RR'=G6WXKTAY!`"TD'=.@&0^E
M+X`\>^6'BQ0^0'D=RMY&<C9+F&5YE!@THY]Y/Q[':.HQF\D4<9I,:FR&/,L)
MTA45;CCSKY&R@$I&@+H^H+X(\@^%'#-_Y3>"ODIY*<<N\6/5]OG?&MSR[E><
MXO<XP_,9A3+JL:RV7:J;F4DF8TZ_%F)EQ940.#9L@:`:WZ/7U*\A\Y\%S'!>
M7HU2QSMQ)&J9MU<T<5%=4Y_B-NZ[$@Y6S4-=S%1:Q+!A46<PTHL%90XV$I7L
M`)D;.TK:2NGW%Q/AU=350I5E9V5A(:BP:^O@QW9<V;,DO*0S'BQ8S*W'%J(2
ME"23T&@-83FWZJWD[YO>0#/B#],6/_IRJL94N%;<_6$%M5Q-HH*FVKW-*E4V
M)*BX/@=:'$J8G*:=M)Q<:#"6E.)!`D-X>^C;XVU,%C)/*"WS[S*Y9GI;EY)E
M_-^:97=4!M5H[Y*L<P<W#=7`KT.J(:^8,I_LV)*3ND`7MRK]&_Z>W)E!+K(?
M`%-Q=<NM+379?Q#96F!Y%42.P^G*;773'ZN>MA9[@F3$>;7MVD;$Z`BK\/?&
M;G#Z=7U7N..',ZY*R_D7A7G/CCE>!Q%EEI?WCM/>.5%5'OVJJ[Q^;8RJJJSK
M'S3A+R6DE#K+Z'62E"BV@#::_7_+[?Y?OT`:`U3/XAORRNXN1\2>+W']Q*B/
MX1;8_P`Z<CVM<9`;K,H0^^>(*24^SNAB0PY7S+8(<4-R&%)3T&@-A/PP\A:S
MRG\7N&>=X#C/S>=896/Y/%;6@JJ\TJT&GR^K>;2HJ95$R&%([$J`46EH.VQ&
M@&@T!ZD_Y)_LK_Q:`B]^H/'3(R_B1*T(<;%3E'<A0]I^?I/Z8(6D?HUY%?,L
M;GSGR9CRE]U/"SZQ[9?>XNY]A/O1R">EZE/M5VU_HW#''%F*XW.;CLNSG:*2
M4H[7)##LNO"G2"DN265?-Q!W?AW2YTZ^[4?=&.3.4I6+&6LJY@:HFG"5SQ)3
M['M2V=A]',6IY\)RL*+G:>QKO0X5O?P>.F\7E6L2#<9X^M\4DJIGI^7N*AIH
M1%65XIAG=UM@.!L'X7'??[#K>37-:T_IAIVEY',.)#)YSR84LSLO9<A2.VY&
M/%OJNXCO&Q\G7,B]:M.5O3(*NWLEW*N[[2_<1E9!:1(<URJH`Q7+=F0XK4-3
M0@NR.Y;[D-Q3ZUI>7W?B5OUUW[D;6N8N8-.CEW\3$CBXU;D;2C16T]ZB^+WE
M3_$<=G8UG&MQ<I-WFDI;=[1:N78G"D8\\*:374=3.6XK)K6VFNFUES$O%9K2
M&67)2XZ5?$I#?:'>X!1`UU_FSE+3Y\OW,[E=VL72,F<Y9%R_25R[<HJJ->%I
M0W[MO$?5@ZME.]!2JVO=2W);O57U^PCPY2QZCBJD(KS+L2DJ*9C[+=;&Z]P<
M$6$E;SZD-]2%+(W]G37F#UIY7Y<Q7/(P9>?E0JW*FQ-;:DT\O:ED7+<(3W-I
M#U^"3?I<(.HVV"<UR/;_`.'`UZ$_+P_^?'_W[*_F\8A[JQ_[7;_U2_2QSM;S
M6_=^G>1]+>4._38=Q*@G;W]=^OL(]WW:O*$%_#N+4/U&?-WS'YGRQH7?`/">
M`Y-X-\,E:42*RPO<GA.CF[-*KO:]-V<EY\0VGAU0TI':K<:`A8^DOR+?^"OU
M-,K\9^1I;M;49U?9+X[9,)CRTL)RW'+B3)XRNDJ)#2UVSS:6DN;$EJT'Q$$:
M`W=P24IW&QV&X`(`.WL2%!*MA]_70%=`:V?\2GUX$\9!_P#NC(__`,&FZ`<G
MZ$H__FYQ$.I)RSE?V`=.W/+@*W)("=BGW[:`R1]8CF#$>)?I\^03643XD:SY
M&Q/_`&XPRJ=?9$Z_R#*9D:*&*^*XI+C_`.60/6ER%)!##+)4H@;$@11_PZ7B
MIR3B#_*WE1F%+-QK"\XQ"NXWXSCV,1Z!*RZ+&N6KB^RR)'?:0Z[CS#\%F-%D
M$]DEPN*;*D)[B`U/\03Y+7?#_BIB_#6)V+];>>1V42\>OY<1QQJ4UQSBT:/9
MY3$0ZWL66KN7*A0W5`@EAQQ(_%H"V_X>'QUH<'\7LI\B)D!A6;\W9?;TT&R+
M*#(A\>X'-<IH%=$?/[Q$>UR)N=+>]A4L('7L&@-A([;]`$_</8/T:`-`8_S#
MBOC_`#[(./LJS#%JN]R+BK(I.6\=7,Y#ZIV(9),J9M%,MJAQF0PEM^543W6'
M$N!QM:%=4D@$`9`/7KH"SN0L\QOC#!LRY%S*P9J\2P7%[O+\BGON(;;8J<?@
M/V4Q>Z]DDAE@@#<=RU)3U)T!K>X?XA9)YJ?3=\RO)W.:-2^>?,3,[GR6XTB2
MD%,ZCQ+B-V<QPMAL;N/KM0['%(4V,&QVAQJQ2K8G8Z`LC^'"\F2Y%YB\2K^P
M=5Z.W-7&D.:I8>#+[L2DY%IXR%CN2IB=^7S0T-ME/.JVVWV`VJOT[[_M;%7\
MI'3?]&@/4G_)/]E?^+0$9'GU(]#,^)E%E#H_)LH.SC?>V"+"D]NSC:NJ2?9K
MR4^9!DPL<\\EQN6E=B\+/V.O[[%[51KZR?.CL'/2M2I/@?F6N[_)N=Y\WAV?
M+GML)K\1QRQ0C?NF2X#S4*/Z8V*IUF_9,QF@GW`[G;V:MZ'9,IXN/\)H^`XI
MJLKTI\"V;YMW8TCZ:KUF+F>.5CSE>^)E&*K2G#6K[O"SZ?D09M'?X3GT=FLE
M8XQ3C&;E6.K*Z3'[EF;)LHR'RV2&8D]B7\*Q\!>;[=S[-=B_,HM<Y9YAT7JO
MA*UE\N_"JQF+"<KUG"O>%\2\=[NDGM:5#CN2G\3BY&@SVY4O&I3V-JGL[_X2
MZL6YKA1*AI#<Z-Z;K:&D$/#KW`#<+)'<=SO[!UUV7DGKKI6/HL-'Q\[&O8U>
M/BC*+FV]T.&+XN'UU?I,.?RM=MP\_*2X'M^FTR]2S9,S$Y,J7"QEZRNYSME6
MU>5O(84]7!"8S$R(A]38;7-4T5)2H@D;;:G+0\K5K_)5S,U-:;>SK\Y2C:O<
M=NL&EPJW][!2>_BI5^[7>=2G''AE1M6[L[<8[W%)JOI5&Q(^9;-R,N3&G8U1
M54H)(#;==(8=&Y5NI#BY*_621["@JW'LUY\]>]4N68W<3,T;&Q)W%**G!S[=
ME5]XU^DEOEBW;3M265<GXEL:5'Z/=&Y\&G@]PJ\K9"?_`+TR/X6TJ2@?!`]@
M7\7Z];L?+WA&'Y?VHJB_'\K^;QB,^JZ_\KMO^27Z6./K=^W[OT[R/I;R/[ZG
M/E`]XH^'O)>=4,C;D;+F6>+.*(+.SDZ;R#G27:NN=A1@?4??I(1D3^T;`F,!
MN"1O>4$D\),;^H=X@>-G'W"6+^!?&]^BGCS;_)<KM/+'&J2ZS++<JEO7%[D%
MQ5_Z.E?(V#SLE+*F5NN%M+*4[DI*B!!;]83CGR7Q#R0Q#RRY.X(H?'B_Y)=I
M44APWE"OY0KIW(O%S<.6UD+EG65-&BDM7ZQJ&5L+;)>$13@62E8T!N.^(7D!
M5>47C1PWSM6.,AS/L*K)][%;6@_EF604?E66U;B4[>DJOR&'(;"2!\/:?81H
M!D=`:VG\2F=N!/&0_9S1D9_3M@T[0%@?3/\`%GR=Y0^G7BF:^/'G'R_P9D]C
M9<F-8SQZS0X->\3Q[BMRVW92E]$_'I.55T>^D-!<B2U,<4PMPJ0WL.T@1H>,
MG.4:/]0:NQ/ZM-7=\V2:+(9/&"I?.%Y9WM+PCR&+%AFJR-&+N2F\4EXO92MF
M7WEP_0$22S*`4$$`#>NA,0(L6)&K&8<:!'B1X\"/7H99A,06FPF(S#9C!,=N
M(VT`&TH`0$_AZ:`U7/XE_'+7U/$?+T]QHPOE/%'U?'Z;-M):Q>XC@G;T@\_`
MBO%"3\2PV=@0-`2E?1"R>JR/Z;/`T:L4@NXI)Y#Q2Y0`@*:MX&?WTUQ*PGJE
M;D6R:<^+J0O?V$:`EDT`:`-QUZ^SJ?N'7J?U']6@#0$&'UKN1LWSG%.&/I]\
M*0CD/+OE[ET;\[Q]BWBTJQQ+A$M%S?,6-I+;>9I*[)[&(EA<MQ"T(C1)&Z5`
M$:`8+$N4?J,8-BF-83C?TYN):W&,/QZKQBBK6_,3%2U#HZ.N8K*^&$'`PA0;
MAQ4))5[>I.^YW`U5)]ORG]-?ZH5!R7R#Q\QQ$J%R0WG]KQ]295%S.G@<-<L3
MK-G):6NR:"Q"C7\"!53Y?I*#2%-O0TH4D*2D@#?KK;&!;UT"VJI;,^KLX,.R
MKIT=:76)D"?';E0I;+B/A6S)C.I6E0Z%*@=`?73_`))_LK_Q:`BX^HBX]%R3
MB>8E)"!5Y6VEQ2"6E/)DTSWI%7L"U-I)&O)?YD]C*ES)RGD6+;<+>#G<4]RC
M][C=OI[MY/G1OR)8&H0NIN3NVJ4?ZLQ;N/,Q<F*:C6%BN+"BEM;CKJW'(T=+
M92?^EB!7:N2=MD]NQW]O3?6J_2#GK(;6#?R7#3ZI2<G2+7:N'9)+TG>=?TS'
MA:<K,7.<E[(^F2[5ZAY<-Y'IK)F3728C3.!4=5+FV-9+0W.=R13_`&1V$7`<
M;4W+E6,YU(2UL4)2.@Z'7H;T[ZBZ!JUR>B_!V;7(F%;E)6YM361)_O7)RXGL
MV4IO9#NJ:/G8\_B;$Z9SE[T4U1;O#VK96K[=Q2KC\.X\SBV5-\>XG$D3KBV1
M8EB,IQN&S`DQ@U)@Q93TB.P['5)"@`GM^`[#J-9M%L](>7%H_-V/H&#'.S\R
MY8DH2GPQ47#QN,[DH_QME$D?+*7,69)Z?.^W84*QJNSL3:VU[W]1;_(G(L:0
MNPQ?)):7!729'Y)D:&FQ*BLOJ"H[4A`;+<VGE,/(WV"7&M]QN`==8ZA=5]*4
MLCE?5I16/:E*6'<A5.TIJDHMQW^[&E:T[#D-$Y?NRD\B,:M[&FJ[5VB'\@9C
M.6':Q<UUR,C=#325>O%V9*@DQ4*"VTA0'PJ;V^W7F]U`YZSLK59Z?>R7?P:M
M<5QJ6S]6E&GW-U)IT'2/#&/#%7*JFQ[_`$$E?@@AU/!*'G`=I68Y(ZTH@@.)
M28;"BDG\02ZVH;^S<:]8_P`@3GB?E]C<R(2C:N:OD78M]JE&Q%+_`#-^[:0+
MU6M1ES<K<9)NW:5?75[!S2L#8[GVJV[=BH%/4G8]`!]IUO!!-12EL9&[:;JC
M7EYLR>!Y\?6!X:\<ZZ4U<<)^"5=8<P<FL,+2]76_*\1ZO$2JE$E+,IFHM7ZN
M"I/Q'U$R4';XM[@;#B5=VRMR=]E;]-SOUW]@'_`:`BY^L1XW#R/\%N4H=7!^
M>S7BB,CF'"0EH.253\+C2Y&0P8RD)+Q7;XH_.1V#HMT(WZ#0$4?\.7Y31':S
ME;Q%R6V;8F-3$\N<3P9LE(<EP+)MB!R!3U27%$NF%*9B6`81U"'GE@'96@-J
M'=)1W)/=TW2/85==NF_Z/OVT!K8?Q*CK0X(\8VBM(<5S%E#P05)"E(9P=]#G
M:"H;E*Y*`?8`5==M`.5]")Q"_IN<3I0XVLHR[E9IT(6E?IJ_UW:*6TX$J^%S
MM6-TJV(WWT`E'U]?I^(Y`Q#_`-:?%M`'<PP*J9J><*:NCEQW)<!C?!69NIAM
M'JOV.%%?I35I^)=6YW'?Y8:`R']#+ZBW^]_'S?B;S#?.2>8.*Z%*^-[VTD@R
M>2>,:[M:9KTNOK]>;D^!M%$9Q.WJR:T-/;*]-Q6@)'/J5>'4;S>\5LOXMK78
M4+D.E?:S7B>VFK::8BYS1QY7RM9,?<23%K<EB/O5\AS\(;D!?L3H#7;^BQYG
M.>%W-7(WA7Y.,S.,*/.,R":S_5S+M2CCCF:.$5#]+D"Y)3'KZ7.X+$=#<Y6T
M8S&6EA?HOAT@;D22E:0I.Z@1NG8;A8^U"@>Q6XV(V/4'0'%2@@$G8`;]2=@`
M`223[@`-`1.?4T\\9/CQ6<>^/O"&00#Y;>0F:X9A&!0V6X-U(X\Q_)<DKZJS
MSZYJWVID5+AC25L5T>2WVR)*RYU0T20)4),F/44[LJYLF&H]16+E6]Q/6W#C
MML5T7U+"TEN*"&(\<--K>=4=D(1N?8!H"`#Z<$W_`-<?U`?+?Z@UJ7I?'O'P
M;\;O&]F2E19C43+'K6MU"1^]##EC0,HD+(V5_P#/'"=C[`-A,@*&QWZ^_P!A
M!(_%[AW#??;V;Z`UF_XCSQO9R#B[A[RDIZYARUX\O'.+,ZD):;6Y*P[,WOF\
M;<>[RCN%7D\=;2"H[)_,%#WZ`=SZ(_E+'\A?"G#\2N;5N5R+X_/#BG*HDE_N
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MVW1;5+M-E(<QZ'K=B.5C9&/!7%1PE<@I>KA;4M_H/OU&>WT&`:YJ)9MMN2$2
M9"EPYNZA')5$2"&MSZ!4HCK[3O[=<II?,O4;1M*AIMC`U+@4JRICWJM=WN&"
M>'I-]^*_C_[R'^$NJ5R?:OTU?##$_LB2;%TMFMED]LKY52AMZ'=\1:_X:[A>
MZ@\]9.C8EN&G:G&./FWKD(O&OII/RZ.G!6CI[3Y[.EZ-'/J[^/P^7O\`,C3Z
MZECWV8WURU&2N+;//L1&XB5)@35*4RA)3&6262?60TLHW_$`.NH^YBU3J'S1
M<A<^!U.#G#Q?\+?<F^Y?=MHY'"P=.MQAY.3CI<4G+[R'HIOEZS[7&G`'*O+-
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MCY6`I;24Q8Q<[R'`X%)`U(DMYQ\HJ$G!;D1B<(?1"R;QIY#E<L\!>>_,.$\D
M6$6RBWE];\98+EC&3QK>4+&S;R>LMI_HWS<ZS2)*R\5/?,#U$K2O=6J%";[C
MFCS'&\%QBAY`S5'(N:U=6W%R3.FL;@X@G)[-*W%.6@QFMDS(%0IU"D@M-.+2
M5)*O:2-`*)Y5^+OD9Y%/9/CV(>:.2\#<0Y7BZ<9N,"P[A_"LANY;,F/*A9&[
M_N!<3Q>1V+V-("%ML-M%E&X0Y\1T!%5B/\.=A.`7M'F6`>9_-F%YMC$QBPQ[
M*\<P[%:RSJ)L;?Y=^`[$L&I;*0E6RD^KVN)Z+!'30$OW&?"'E5A?%F?X5EOF
M?-Y1SJWKH,3C/E6_X(P:HM^.I+#):FS;:BJK5FFSYZ8H)7VR_ERWV^U9).@(
MY^?_`*+G('E==U>1^2WU!^8^3YE$S+8QR!&XLX^Q7'\<;G>F)_Y-CE5/_*8;
MT]#*$O.EI3[J$A*G%`:`N[Q]^D]SIXBULVD\;OJ,\I87BUI9+MIF%Y)PQQ]G
MF)+M)"$"38IJ+>U0*V5*#*0\N(J,73U65'0$S'Y4U98^:+)4P\B9L*;\GR`3
M(+(@7[4F&8-H954H.1VXEJE;G?'^)`0X4=1[0->9S^'>XWK.5[GDGC;RJY:X
ME:1EUAD_']3A>,U,6WXY:??^9@UM+F#MVBP?:J7'%M,N^FVHQ@EM6X"BH"7;
MQMX,\C.'I]A'Y>\O\D\EL352M5U!79CQ7@^(9/4V33[95;SLPQ>4)=[ZL-*F
ME-OL`J4KU"HGIH"Q_,?Z;7BKYOQ&Y'+^%O0L[B0%5M3RMA$AC'\^KHA"E,PY
MEDN/)A9!6QG""B/8QY32/:CL/70"M<6^#WU%?%ZMCXAX^>?.(\E<95@0Q0X/
MY2\0S\F>H(+94(U=6Y9BV11[YB+%2D(0@*^7;0D!#+8V&@,E9#PM]67D*OD4
M]WYD^-7"U=,:5&FV_"_`>1W^6-,/)*'5U=ER'E+T2NF(!_=NH84I)ZC8]=`8
M)X*^AOQ7Q=S]AWDQR3Y%<V\\<N8EG%?R`Y;Y@C'HE?D>2UJ5F!+OP6;J[F,1
MY;B74(^?`0I"0`$#;0#-^6_@_P`\>7$C,L2M_.+/.+N",L99C*X?X\XJPZ%(
M?K41H[$ZMR#D&39+R*^@6,MM;KD=26&UMN!"DJ2""`O/C3])OE_PR-O#\:_/
MGD/%,9R6U@W>485D_"W'F88W=6$,1HKDIJ-,L(SU/92:F.(RY,8H66TM]W?Z
M24Z`FM"5%"4]VZ^Q(*]NWO4``H]/\OO/W'MW]^@(C/*OZ;_/7F/"R#"N8//7
M-(O#EAEKV1U?%>'\&<?T<&)$AV#\O&ZFXR)FW<N<C-`A:$I<=4A+SK8=4CN`
MV`6?AKZ$EEXYY<QR%X^>?'.'%F:)C?)2K>NX^PJ7%M:_UOF5U5[22;!JLNJ_
MUE%1:E-/("R5)^+KH":S$\&YDJN#;#!LGYR&5\QR,;RZL@\YIXWQZB_+[ZV3
M:IQ7)O\`;B'-?QZ6K$OFHJC%4\&;`Q/WG8'5``9I?/Q)'V@ZNC&3?$G2*W@\
MBD=W0H2H$G=)`V.X.X[5=R=_O]^OFRL'`S%QWX1N)=DEQ1?KBZI_4RJEP/B4
MN%KM[CK^69_\LU_W6_\`PZX_\'T7^J8?]GC^P9/BI?OY?3V!\LS_`.6:_P"Z
MW_X=/P?1?ZIB?V>/[`^*E^_E]/84^6C[@JC,[)WV^$#K]W8!JR6C:1Q)PQ<%
M27:[,8OV>%%\,F^ZJU<<^_T'?TV[?<""CX00G^M[@02/?U.N6M4LP\NW&"AN
M\&Q&&=FY-^9.6U=ARUD+3@ZM;;3CC3:774-K6VTMP,I<<2DJ0VIT@AI*U``J
M(V3OOH!?.#N9+_F*SS^6]BL;',7Q2X&,0)"K1=I86U]#<=-LX7V$,UIA160U
MVEI!)4[U4?<`PVV_0@'?IL1N#]Q`!)!_0=`8QPS/+S)\NS_&K'C[),5KL-GQ
M8=1D=MZ/Y5EK+WJI5)I@V!VM-EGNV25#M4-R%=-`9.T`:`Z5R([;C;"WV4R'
M@X68ZG$)?=#:>Y1::4H..)2/:4@@>_0'=H!=>3>9<BQ'D[CCBV@Q&'93.0+!
MI2+V=:]T>!5PW&UWDQ51$2F:V[`BI46UK<0VM7LWZC0#%GVG;V;]-`4T`:`-
M`&@#0!H`T`:`-`&@/4G_`"3_`&5_XM`<'_Q)_0='MBXO<P=&J02MKAAL0W['
MN#5W%+O9;P0[E]0:<4N]C@AW+Z@UCG"%VGF).FZI=&D?=V5#2-N$?=5"C577
M:&KRI@CR4Y)'%W#^59!%>].]G1ACF.HV4I:KJ[2J)'>:;;/K+,-AQ;Q[>H],
M?;H!6L1L>7>$,6\?\>IH&.UF.9=E]/CT[&+&$_*SS)'[K>QR#)+26XXABL<2
MVLJ0PA!=:8;2IY84>U(#J\GYC.P;$K3(84>.XBOBSI4NULG4M4])!B1')!LK
M!MM:)4\DA+3,=@AQ^2XE&Z4DJ`%K>/F2\A9?Q70Y5R28B+V]786L1$6O33,(
MQ]YU+E$9<3UI'R<A^'LM6^ZNU77KL=`8WB\OYGR4YR7D'']K78KQEQFQ<Q6L
MGG4Z+FQS7):>$[,EM0F9*F8<+&H99[%+25/NE0V4DGH!F;B'D"3R9Q9AV>O5
MWR=AD5()DFL94$-HL&7)$1Y+*W`OTX\F9%/9W=$)6-R=M]`)C&>Y%Y:YAY7Y
M7IKBKPA?"&.SL1QU;T%K,*]RU:BRYUS'!>56QTK4&%I>D-!13W@(W&RM`-KX
M\\E6O+G$N,9O>PX\"ZLFYT>P1!;6B"_+K9KD)R5";6IPM1I(:[@@J40O<;[:
M`5^@NLGY/\J.3<DPJ/%>>P&F8X[QO(+IAZ3C&,H0\X;Z[6W&=:7;6DU_U6HT
M-M3:G`LN.+2VVG<#.GC;R-G6>-<H5N=S*>WF8'GD[%*Z_J*\54:V8B(<4\MR
M(AY]MM<<H'L5OLH;Z`R%><@R9.0S,)P6/#LL@J8S<W*;JV<6UC&%Q74>JRFW
M<8*'YUQ):05M065)6ED^JZI"-MP,;^/&><A\FOY[F&16]5-PAB_?Q?`X]34-
MU<&T9H9+L>WRAI]Y^78*;GN`):;<=4@;*Z#;0%D<L\Y<I8ER_P`<X1CE93O,
MY)96#2L4^5_,<@R"JAA+4:T?LV7U1,?BVTE+I91VE<>.RI]Y6VR"!G?C>%S9
M&L,I5RI=879US[T%[$F\6A2H+D!+K3QL(5BN2V5.QXKBFTM+)4XX$E>XWV`"
M^Y=SSRPSSYB/&>)TM3(;GU\ZPML/=C_,6T:"LOM55GD=^RZ]&IH[K21-<0T@
MEF+Z:25.O!(`^%B_/7+UKD_-U,Y>8;88WQZTXZOD7_3KL'&,55`;E+LV4P/S
M(R\DD/+;#,-KU_WBT%U:@@A)H?3Y<*)TVL8?QPR[/L[XFQ_+>1TPA>7CTV;`
M<AP4UADXZ[(4*67*@(<<1'D2XZ2L=IV6@I4/;JIBN*,94B?6M>1I,^TO:'"5
MU#@Q%#B\XS6^+J\4Q);41<QRL"(ST9VYOV8H#KS*'&VHK9!>6"0A0QED^->:
M\B\EX[DN>YG8PGZ*]R&PA\?5]?4MU<=C'Z=V3`_..]7KRWA=26@XCU7'0$CX
M>F@&5Z^\;'W@'<`_8#TWVT!ZD_Y)_LK_`,6@.#_M3^@_]N@.C0!H`T`:`-`&
M@%0\@\.SC(\_X6O:G#96?87A5Q97E[C<*SJJ^4[=^B&Z2<ZBVE1(\B'#<'<=
MRK;[#H#(>,8!?7.:M<I\E+B?ZAKJZ1489BE>^9U1@]?,4GYZ4NP6VVFYRNT;
M2!(E(0AEE(])L$;J(%B>2^&\A\A,X)AV*T+=OB-AE$2TY%!NX],E^MJ5-2(%
M3)<<7\PBKL)25+=+25N$([0DG8:`S[!I;).)+HK.<PN>[4R*Z1/K8GY?7QC+
MCO,-MUD=L'TXE0AQ+3!_%VM@JZD[`)E0\0\J1N%*KQVB5"<8C3;"VB\A<D.V
M-:_!?Q^PN7YSJL3B0Y#]C9W-Y$4VWN^RP(X"@HZ`9'-;:AX"X0M9=3&1$JL#
MQ)%?0PTJ4I2YR6TP:QK?HMYZ1.>2M1]I/<=`+;QI@'*;?`D;BR!C+^-9#R"J
M;;9SR):SJMV!$J\N<$R=.KXT::]<6&2NU+J8[3#L=M#+P5WK``W`;*MQ+_;C
MBX8CQS6)=?QG%95=BU>[(;8$RU1$=^5=ERGBEM#TZP7ZCJE';N).^@,`<9X?
MROPSA^*X3C?']=D%WD]=<Y!G^<R<EKXC%)G-F^XMA<UA;+DB[K:UMX$^EWJ4
M$!*!OOH#.W&O'$7BW!F<8IG!96B396]G;R26%W^5V87*GVTQ(W#(G3R`$=Q2
MAL)2-`)3'XZ\G7>`\YQ%O&(5)EF29);660SF,B@RLJSIR^NFOG7$O!SY"FK(
MU2D,[+?4^N.E*$);'=H!RN&\/N,%P2DQRW9KZMBLKHD.NHJYQ,QJDC-1&F'6
MI-JE"%W-I/L2Y*E/!/IH6X4-_".Y0%@<?<7Y$YSAR7S)G=9&:EO*9Q/C.*B9
M'F+A8A!82V_;$M%T0IMDXV$!(^/M6K?\6@&3E+>;BR7([+DF0B.\XQ&0XEE<
MEY""MJ/ZRMT,^NXD)*CT3OUT`F.+\6\M8K@'*N?(J($[R-Y7E3EE#EK"$3$Z
MF9,,*O@0K11+"FJ2`X'R$*'J.(;2!LC;0'PLXX!S''>(^->&^/Z,7E-:Y1!M
M^:+-NYBT\J[:C%FQM!*L)?[U,.WL_@44I<4AAE(2G<]!G5V-:M.O8-S'K<JJ
M,#E5D5^MDY6Q16+=08,5$"GAV7Y?)-'60FR2!!K7/29;6[\;B$!:_B4=#'.2
ME*J$)LN+O).?XXUW'</%V*.;)NF_]70(.005Y1G!N;65.R"]NK)]Y$"JA+#J
M4.1RZ\Z\4CN/I)""+!\N-,>LL6P^JH[%NOAIKV&8E92U25+@X_4Q([,6#4)G
MN(;>MY3:&2[(E*2D.R'5]H"`G0%^Z`]2?\D_V5_XM`<EM]Y!WVV^[?\`YC0'
M7Z'[?]W^?0!Z'[?]W^?0!Z'[?]W^?0!Z'[?]W^?0!Z'[?]W^?0!Z'[?]W^?0
M!Z&W4*V.X.X&Q)'L)^+W:`H(P&Y"MM^IV'3?[=N[;<Z`H8J222KJ=NNQZ$=`
MH#NV"@/?H#GZ2NO[P[D=N^W4#[!\70?HT!Q^62#W`IW&Q&Z>@[00!L%;#;?]
M/70"\\Y<,9=S&S3TS>:TM!B=3>5F0/4KN+R[1Z\EU;R'F(MQ,&0P4+KN[N_=
MMM(.Z@2HE(T!GZ+$?3&CIF+BJE)8:;DF$PMB(IQ'7_IF77GG6F4J_"E2U$#W
MG0'H,??^F1]Z=TGV;>T*!]AT!3Y1&^_P^[<=FP/:=T@@$`A)]@]F@.7H?M^T
M$>SW$$'^E]AT!3Y?[%D;[$[`CN(``*CW;J(V]IT!41]CN%D?$5;;?#W$[]VQ
M5MOOH#B8H(V*B1VA/4$[]H(!/Q=5#<]?;H"IC[C\9&VQ!`(((]A!"M]]`<@R
M0-N_IN3U2#U))^WW$]/LT!Q,8'J5;D#8**=U`;J/0D[@@J.@*B/L-@KM&Q&P
M3M[?:>BO;O[_`&C0''Y4=-UD]HV&^Y^';8IV[MNU7O\`MT!R]#]O?[R-S]PW
MWWV&@#T/V_[O\^@.T(V1V;^XC?;[=_=O]^@.>@#0!H`T`:`-`&@#0!H`T`:`
>-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
